Filters
| Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
|---|---|---|---|
Molecular Vision Laboratory United States | 1358 | 1028 |
|
Centogene AG - the Rare Disease Company Germany | 417 | 413 |
|
Invitae Macular Dystrophy Panel Invitae United States | 66 | 36 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Invitae Inherited Retinal Disorders Panel Invitae United States | 486 | 293 |
|
C1QTNF5 - Late-Onset Retinal Degeneration (L-ORD) Translational Metabolic Laboratory Radboud University Medical Centre Netherlands | 1 | 1 |
|
Stargardt Disease and Macular Dystrophies Amplexa Genetics Amplexa Genetics A/S Denmark | 2 | 23 |
|
Molecular Vision Laboratory United States | 342 | 268 |
|
Stargardt Disease (STGD) and Macular Dystrophies Panel PreventionGenetics, part of Exact Sciences United States | 35 | 28 |
|
PreventionGenetics, part of Exact Sciences United States | 91 | 82 |
|
Autosomal Dominant Retinitis Pigmentosa (RP) Panel PreventionGenetics, part of Exact Sciences United States | 32 | 30 |
|
Baylor Genetics United States | 842 | 637 |
|
Institute for Human Genetics University Medical Center Freiburg Germany | 1 | 1 |
|
Genomic Unity® Retinal Disorders Analysis Variantyx, Inc. United States | 1 | 394 |
|
CGC Genetics Unilabs Portugal | 1 | 203 |
|
CGC Genetics Unilabs Portugal | 1 | 306 |
|
Diseases of the posterior ocular segment (WES based NGS panel of 307 gene, including CNV analysis) CGC Genetics Unilabs Portugal | 1 | 307 |
|
Stargardt disease and macular dystrophy (WES based NGS panel of 15 genes, including CNV analysis) CGC Genetics Unilabs Portugal | 1 | 15 |
|
Retinal degeneration, late-onset, AD (deletion/duplication analysis of C1QTNF5 gene) CGC Genetics Unilabs Portugal | 1 | 1 |
|
Retinal degeneration late-onset, AD (sequence analysis of C1QTNF5 gene) CGC Genetics Unilabs Portugal | 1 | 1 |
|
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.